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Original Article

Sofosbuvir, Velpatasvir, and Voxilaprevir
for Previously Treated HCV Infection
M. Bourlière, S.C. Gordon, S.L. Flamm, C.L. Cooper, A. Ramji, M. Tong,
N. Ravendhran, J.M. Vierling, T.T. Tran, S. Pianko, M.B. Bansal, V. de Lédinghen,
R.H. Hyland, L.M. Stamm, H. Dvory‑Sobol, E. Svarovskaia, J. Zhang, K.C. Huang,
G.M. Subramanian, D.M. Brainard, J.G. McHutchison, E.C. Verna, P. Buggisch,
C.S. Landis, Z.H. Younes, M.P. Curry, S.I. Strasser, E.R. Schiff, K.R. Reddy,
M.P. Manns, K.V. Kowdley, and S. Zeuzem, for the POLARIS-1
and POLARIS-4 Investigators*
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Patients who are chronically infected with hepatitis C virus (HCV) and who do not
have a sustained virologic response after treatment with regimens containing
direct-acting antiviral agents (DAAs) have limited retreatment options.
METHODS

We conducted two phase 3 trials involving patients who had been previously treated
with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1
infection who had previously received a regimen containing an NS5A inhibitor
were randomly assigned in a 1:1 ratio to receive either the nucleotide polymerase
inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor
voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks.
Patients who were infected with HCV of other genotypes (114 patients) were enrolled in the sofosbuvir–velpatasvir–voxilaprevir group. In POLARIS-4, patients
with HCV genotype 1, 2, or 3 infection who had previously received a DAA regimen
but not an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive sofosbuvir–velpatasvir–voxilaprevir (163 patients) or sofosbuvir–velpatasvir (151 patients)
for 12 weeks. An additional 19 patients with HCV genotype 4 infection were enrolled in the sofosbuvir–velpatasvir–voxilaprevir group.
RESULTS

In the three active-treatment groups, 46% of the patients had compensated cirrhosis.
In POLARIS-1, the rate of sustained virologic response was 96% with sofosbuvir–
velpatasvir–voxilaprevir, as compared with 0% with placebo. In POLARIS-4, the
rate of response was 98% with sofosbuvir–velpatasvir–voxilaprevir and 90% with
sofosbuvir–velpatasvir. The most common adverse events were headache, fatigue,
diarrhea, and nausea. In the active-treatment groups in both trials, the percentage
of patients who discontinued treatment owing to adverse events was 1% or lower.
CONCLUSIONS

Sofosbuvir–velpatasvir–voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment
with a DAA regimen had previously failed. (Funded by Gilead Sciences; POLARIS-1
and POLARIS-4 ClinicalTrials.gov numbers, NCT02607735 and NCT02639247.)
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T

he majority of patients who are
chronically infected with hepatitis C virus
(HCV) can now be successfully treated
with drugs that directly target viral replication.1,2
Combination regimens of direct-acting antiviral
agents (DAAs) provide rates of sustained virologic response exceeding 90%, regardless of HCV
genotype, disease stage, or treatment history.3
The proportion of patients who do not have a
sustained virologic response to treatment with
approved regimens is small, but given the size of
the infected population — estimates range up to
150 million people worldwide4 — the absolute
number of such patients is substantial and will
increase as more patients are treated for HCV
infection. There are no approved retreatment options for patients who have previously received a
regimen containing an NS5A inhibitor.5 These
patients, who represent the majority of patients
with recent treatment failures, are of particular
concern because the resistance-associated substitutions that are selected by NS5A inhibitors
maintain viral fitness long after the end of the
failed treatment.
Sofosbuvir is a nucleotide analogue HCV NS5B
polymerase inhibitor that, in combination with
other DAAs, is approved for the treatment of
HCV infection of all genotypes.6-8 Velpatasvir is
an HCV NS5A inhibitor with pangenotypic potency.9 The fixed-dose combination of sofosbuvir
and velpatasvir provided high rates of sustained
virologic response in phase 3 clinical trials and
has recently been approved for the treatment of
patients with HCV infection of any genotype,
with or without cirrhosis, regardless of whether
they have received previous treatment with interferon-based therapy.10,11 Voxilaprevir (formerly
GS-9857, Gilead Sciences) is a pangenotypic inhibitor of the HCV NS3–NS4A protease.12-14 In
phase 2 trials, the combination of sofosbuvir,
velpatasvir, and voxilaprevir was effective in a
broad range of patients with chronic HCV infection.15-18
We conducted two phase 3 trials to assess the
efficacy and safety of the fixed-dose combination of sofosbuvir, velpatasvir, and voxilaprevir
for 12 weeks in patients who were chronically
infected with HCV of any genotype, including
patients with compensated cirrhosis, who have
previously received unsuccessful treatment with
DAA-based regimens.

n engl j med 376;22

Me thods
Trial Oversight

The two trials were approved by the institutional
review board or independent ethics committee at
each participating site and were conducted in
compliance with the Declaration of Helsinki,
Good Clinical Practice guidelines, and local
regulatory requirements. The trials were designed and conducted by the sponsor (Gilead
Sciences) in collaboration with the principal investigators, in accordance with the protocols,
which are available with the full text of this
article at NEJM.org. The sponsor collected the
data, monitored trial conduct, and performed
the statistical analyses. Independent data and
safety monitoring committees reviewed the progress of the trials. All the authors had access to
the data and assumed responsibility for the integrity and completeness of the reported data
and the fidelity of the trials to the protocols. The
initial draft of the manuscript was prepared by a
writer employed by Gilead Sciences and by the
primary investigators (the first and last authors)
with input from all the authors.
Patients

We used identical eligibility criteria for the two
trials, with the exception that POLARIS-1 enrolled
only patients whose previous treatment included
an NS5A inhibitor and POLARIS-4 enrolled patients who had been previously treated with any
DAA regimen that did not include an NS5A inhibitor (with the exception that those who had
received only a protease inhibitor with peginterferon and ribavirin were not included, since these
patients have approved retreatment options).
Patients had to have had virologic failure after
completing previous treatment of at least 4 weeks’
duration; patients who discontinued owing to
adverse events or who had virologic failure because of nonadherence to treatment were not
enrolled. All patients provided written informed
consent. The full eligibility criteria for both trials
are provided in the Supplementary Appendix,
available at NEJM.org.
Trial Design

In POLARIS-1, patients were enrolled at 108 sites
in the United States, Canada, New Zealand, Australia, France, Germany, and the United Kingdom
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from November 2015 through May 2016. Patients
with HCV genotype 1 infection (with a target of
having at least 30% of the sample made up of
patients with compensated cirrhosis) were random
ly assigned in a 1:1 ratio to receive sofosbuvir–
velpatasvir–voxilaprevir or matched placebo for
12 weeks; randomization was stratified according to cirrhosis status. The investigators, patients,
and study personnel were unaware of the studygroup assignments for patients with genotype 1
infection until after the post-treatment week 4
visit. All patients who were infected with HCV of
other genotypes or an indeterminate genotype,
regardless of whether they had cirrhosis, were
enrolled in the sofosbuvir–velpatasvir–voxilaprevir group, since patients with non–genotype 1
infection comprise a comparatively small proportion of those who have virologic failure after
treatment with a DAA-based regimen. Patients
received either a fixed-dose combination tablet
containing 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir or a matching placebo tablet, administered orally once daily
for 12 weeks. Patients who were randomly assigned to the placebo group were eligible for 12
weeks of subsequent treatment with sofosbuvir–
velpatasvir–voxilaprevir.
In POLARIS-4, patients were enrolled at 101
sites in the United States, Canada, New Zealand,
Australia, France, Germany, and the United Kingdom from January through May 2016. In this
open-label trial, patients with HCV genotype 1,
2, or 3 infection were assigned in a 1:1 ratio to
receive either sofosbuvir–velpatasvir–voxilaprevir
or sofosbuvir–velpatasvir once daily for 12 weeks;
randomization was stratified according to HCV
genotype and cirrhosis status. Patients who were
infected with HCV of any other genotype were
assigned to receive sofosbuvir–velpatasvir–voxilaprevir for 12 weeks.
Assessments

For both trials, screening assessments included
measurement of the serum HCV RNA level,
IL28B genotyping, and standard laboratory and
clinical testing. HCV RNA levels were measured
with the use of the COBAS AmpliPrep/COBAS
TaqMan HCV Quantitative Test, version 2.0, with
a lower limit of quantification of 15 IU per milliliter. IL28B genotype was determined by polymerase chain reaction amplification of the single-
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nucleotide polymorphism rs12979860, with the
use of TaqMan MGB probes.
The Abbott RealTime HCV genotype II assay
was used to determine HCV genotype at screening. HCV genotype and subtype were subsequently determined by analysis of NS3, NS5A, and
NS5B sequences obtained by deep sequencing
with the use of the Basic Local Alignment Search
Tool (BLAST); these results were used in the
analyses.
Deep sequencing of the NS3, NS5A, and NS5B
coding regions was performed on samples obtained from all the patients at baseline and from
those patients with virologic failure at the time
of failure. Sequences that were obtained at the
time of virologic failure were compared with
sequences from baseline samples to detect resistance-associated substitutions that arose in association with treatment. We report resistanceassociated substitutions that were present in
more than 15% of sequence reads.
End Points

For both trials, the primary efficacy end point
was a sustained virologic response, defined as a
serum HCV RNA level lower than 15 IU per milli
liter 12 weeks after the end of treatment in patients who were enrolled and received at least
one dose of active treatment or placebo. Patients
whose HCV RNA levels were not assessed at 12
weeks after treatment for any reason were classified as not having had a sustained virologic
response, with the exception of those who had
an HCV RNA level lower than 15 IU per milliliter
both before and after post-treatment week 12; a
sustained virologic response at post-treatment
week 12 was imputed for these patients. The
primary safety end point was the proportion of
patients who stopped taking active treatment or
placebo prematurely owing to adverse events.
The secondary efficacy end points were the
percentage of patients with an HCV RNA level
lower than 15 IU per milliliter at 4 and 24 weeks
after the end of treatment, the percentage of patients with an HCV RNA level lower than 15 IU
per milliliter during treatment, the change in
HCV RNA level from baseline (day 1), and the
proportion of patients with virologic failure (defined as a confirmed HCV RNA level of at least
15 IU per milliliter after two consecutive measurements showing HCV RNA levels lower than
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15 IU per milliliter, or an increase in the HCV
RNA level of more than 1 log10 from the nadir
during the treatment period). In addition, we
report results for the secondary objective of an
assessment of the emergence of viral resistance
to the study drugs. Evaluation of other secondary objectives for POLARIS-1 — the characterization of the steady-state pharmacokinetics of
sofosbuvir, velpatasvir, and voxilaprevir, and an
evaluation of the efficacy and safety of deferred
treatment with 12 weeks of sofosbuvir–velpatasvir–voxilaprevir in the placebo group — are beyond the scope of the current report.
Statistical Analysis

In both trials, the primary efficacy analysis was
designed to test for the superiority of the rate of
sustained virologic response achieved among patients receiving sofosbuvir–velpatasvir–voxilaprevir or sofosbuvir–velpatasvir over a performance
goal of 85%, with the use of a two-sided exact
one-sample binomial test at the 0.05 significance level for POLARIS-1 and at the 0.025 significance level for POLARIS-4, on the basis of
the Bonferroni adjustment for two primary efficacy tests. The planned enrollment of 280 patients in the sofosbuvir–velpatasvir–voxilaprevir
group in POLARIS-1 and of 205 patients in the
sofosbuvir–velpatasvir–voxilaprevir group and 175
in the sofosbuvir–velpatasvir group in POLARIS-4
were calculated to provide more than 90% power
to detect an advantage of 10 percentage points in
the rate of sustained virologic response over the
performance goal of 85%, which was based on
the efficacy of the combination of sofosbuvir–
velpatasvir–voxilaprevir in phase 2 trials. Confidence intervals for the efficacy rates according
to subgroup were not adjusted for multiplicity.
POLARIS-4 was not powered for a comparison
between sofosbuvir–velpatasvir–voxilaprevir and
sofosbuvir–velpatasvir, and no statistical comparisons between the groups were planned or
performed. The results with regard to the secondary end points and objectives were summarized.

gan the active treatment or placebo (Table S1
and Fig. S1 in the Supplementary Appendix). In
total, we enrolled 300 patients with HCV genotype 1 infection, 5 with genotype 2 infection, 78
with genotype 3 infection, 22 with genotype 4
infection, 1 with genotype 5 infection, 8 with
genotype 6 infection, and 1 with infection with
HCV of unknown genotype. Of the 300 patients
with HCV genotype 1 infection, 150 were randomly assigned to the sofosbuvir–velpatasvir–
voxilaprevir group, and 150 were assigned to the
placebo group. The other 114 patients with
non–genotype 1 HCV infection at screening were
enrolled in the sofosbuvir–velpatasvir–voxilaprevir group. Of these patients, 1 with HCV genotype 4 infection never received treatment.
Of the 397 patients who underwent screening
for POLARIS-4, 333 were enrolled and treated:
144 patients with HCV genotype 1 infection, 64
with genotype 2 infection, 106 with genotype 3
infection, and 19 with genotype 4 infection
(Table S2 and Fig. S2 in the Supplementary Appendix). No patients with HCV genotype 5 or 6
infection were enrolled. In total, 163 patients
were randomly assigned to receive sofosbuvir–
velpatasvir–voxilaprevir (78 patients with genotype 1 infection, 31 with genotype 2 infection,
and 54 with genotype 3 infection), and 151 were
assigned to receive sofosbuvir–velpatasvir (66 with
genotype 1 infection, 33 with genotype 2 infection, and 52 with genotype 3 infection). Per
protocol, all 19 patients with HCV genotype 4
infection were enrolled in the sofosbuvir–velpat
asvir–voxilaprevir group.
The demographic and baseline clinical characteristics of the patients in both trials are
shown in Table 1. In each of the three activetreatment groups, the percentage of patients with
compensated cirrhosis was 46%. In POLARIS-1,
the most common NS5A inhibitors used in previous unsuccessful treatment were ledipasvir
(55% of patients), daclatasvir (23%), and ombit
asvir (13%). In POLARIS-4, 85% of patients had
received sofosbuvir as a part of previous unsuccessful treatment.
Efficacy

R e sult s

POLARIS-1

Among the patients who had previously been
Of the 520 patients who underwent screening treated with a regimen containing an NS5A infor POLARIS-1, 416 were enrolled, and 415 be- hibitor, the overall rate of sustained virologic
Patients
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Table 1. Baseline Demographic and Clinical Characteristics of the Patients in the Two Trials.*
Characteristic

POLARIS-1
Placebo
(N = 152)

Mean age (range) — yr
59 (29–80)
Male sex — no. (%)
121 (80)
Race — no. (%)†
White
124 (82)
Black
22 (14)
Asian
6 (4)
Other
0
HCV genotype — no. (%)
1
150 (99)
1a
117 (77)
1b
31 (20)
Other
2 (1)
2
0
3
0
4
0
5
0
6
2 (1)
Unknown
0
IL28B genotype
CC
27 (18)
CT
93 (61)
TT
32 (21)
Cirrhosis — no. (%)
51 (34)
HCV RNA level — log10 IU/ml
6.3±0.6
ALT level — U/liter
74±84
Previous HCV DAAs received — no. (%)
NS5A inhibitor plus NS3 inhibitor with or
62 (41)
without NS5B inhibitor
NS5A inhibitor plus NS5B inhibitor
80 (53)
NS5A inhibitor
9 (6)
NS5B inhibitor plus NS3 inhibitor
1 (1)‡
NS5B inhibitor
0
NS3 inhibitor
0
None
0
No. of previous HCV treatment regimens — no. (%)
1
102 (67)
≥2
50 (33)
Most recent HCV treatment response — no.
(%)
No response
10 (7)
Relapse
125 (82)
Other
17 (11)

POLARIS-4

Sofosbuvir–Velpatasvir– Sofosbuvir–Velpatasvir–
Voxilaprevir
Voxilaprevir
(N = 263)
(N = 182)

Sofosbuvir–
Velpatasvir
(N = 151)

58 (27–84)
200 (76)

57 (24–85)
143 (79)

57 (24–80)
114 (75)

211 (80)
38 (14)
8 (3)
6 (2)

160 (88)
16 (9)
2 (1)
4 (2)

131 (87)
13 (9)
4 (3)
3 (2)

150 (57)
101 (38)
45 (17)
4 (2)
5 (2)
78 (30)
22 (8)
1 (<1)
6 (2)
1 (<1)

78 (43)
54 (30)
24 (13)
0
31 (17)
54 (30)
19 (10)
0
0
0

66 (44)
44 (29)
22 (15)
0
33 (22)
52 (34)
0
0
0
0

47 (18)
165 (63)
51 (19)
121 (46)
6.3±0.7
89±72

33 (18)
107 (59)
42 (23)
84 (46)
6.3±0.6
84±65

29 (19)
95 (63)
27 (18)
69 (46)
6.3±0.7
85±68

83 (32)

0

0

161 (61)
18 (7)
0
1 (<1)‡
0
0

0
0
46 (25)
134 (74)
2 (1)‡§
0

0
0
38 (25)
109 (72)
3 (2)‡§
1 (<1)‡¶

160 (61)
103 (39)

111 (61)
71 (39)

91 (60)
60 (40)

20 (8)
224 (85)
19 (7)

7 (4)
171 (94)
4 (2)

12 (8)
131 (87)
8 (5)

*	Plus–minus values are means ±SD. ALT denotes alanine aminotransferase, DAA direct-acting antiviral agent, and HCV hepatitis C virus.
†	Race was reported by the patient.
‡	The patient or patients were enrolled in error.
§	Previous DAA treatment with only NS3 inhibitors was an exclusion criterion in POLARIS-4, since these patients have approved retreatment options.
¶	This patient had previously received only interferon and ribavirin, not HCV DAAs.

2138

n engl j med 376;22

nejm.org

June 1, 2017

The New England Journal of Medicine
Downloaded from nejm.org at HENRY FORD HOSPITAL on December 17, 2019. For personal use only. No other uses without permission.
Copyright © 2017 Massachusetts Medical Society. All rights reserved.

Sofosbuvir, Velpatasvir, and Voxilaprevir for HCV Infection

Sofosbuvir–velpatasvir–voxilaprevir

Subgroup

Sofosbuvir–velpatasvir

POLARIS-1

POLARIS-4

Overall
Age at baseline
<65 yr
≥65 yr
Sex
Male
Female
Race
Black
Non-black
Baseline BMI
<30
≥30
HCV genotype
1a
1b
2
3
4
5
6
Cirrhosis
Yes
No
IL28B genotype
CC
Non-CC
Baseline HCV RNA
<800,000 IU/ml
≥800,000 IU/ml
60

70

80

90

100

60

70

80

90

100

Sustained Virologic Response (%)

Figure 1. Rates of Sustained Virologic Response According to Subgroup.
The position of the square indicates the rate of sustained virologic response, defined as a virologic response at 12
weeks after the end of treatment, in each subgroup; the horizontal lines indicate 95% confidence intervals. The vertical lines represent the overall rate of sustained virologic response in each treatment group. The subgroup analysis
did not include patients who withdrew consent (two patients in POLARIS-1) or were lost to follow-up (one patient in
POLARIS-1 and two patients in POLARIS-4). BMI denotes body-mass index (the weight in kilograms divided by the
square of the height in meters), and HCV hepatitis C virus.

response in the sofosbuvir–velpatasvir–voxilaprevir group was 96% (95% confidence interval
[CI], 93 to 98), which was significantly superior
to the prespecified performance goal of 85%
(P<0.001) (Fig. 1 and Table 2). Of the 253 patients with a sustained virologic response at
week 12 after treatment, 249 returned for the
post-treatment week 24 visit. All 249 patients
had a sustained virologic response at that time.
None of the patients who received placebo had a
sustained virologic response. The HCV RNA
levels and changes from baseline at each visit
n engl j med 376;22

through the end of treatment are provided in
Table S3 in the Supplementary Appendix.
The rates of sustained virologic response were
96% (95% CI, 90 to 99) among patients with
HCV genotype 1a infection, 100% (95% CI, 92 to
100) among those with genotype 1b infection,
100% (95% CI, 48 to 100) among those with
genotype 2 infection, 95% (95% CI, 87 to 99)
among those with genotype 3 infection, 91%
(95% CI, 71 to 99) among those with genotype 4
infection, and 100% (95% CI, 54 to 100) among
those with genotype 6 infection. The single panejm.org
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Table 2. Response Rates during and after the Treatment Period.
Type of Response

POLARIS-1*

POLARIS-4

Sofosbuvir–Velpatasvir–
Voxilaprevir
(N = 263)

Sofosbuvir–Velpatasvir–
Voxilaprevir
(N = 182)

Sofosbuvir–
Velpatasvir
(N = 151)

no. of patients/total no. (%)
HCV RNA level <15 IU/ml
During treatment
At 2 wk

149/263 (57)

114/182 (63)

85/151 (56)

At 4 wk
At 8 wk

243/262 (93)

161/182 (88)

137/151 (91)

262/262 (100)

182/182 (100)

149/151 (99)

At 12 wk

260/261 (100)

180/182 (99)

149/150 (99)

257/263 (98)

179/182 (98)

138/151 (91)

Any genotype

253/263 (96)

178/182 (98)

136/151 (90)

Genotype 1a

97/101 (96)

53/54 (98)

39/44 (89)

Genotype 1b

45/45 (100)

23/24 (96)

21/22 (95)

After end of treatment
At 4 wk
At 12 wk†

Other genotype 1

4/4 (100)

0

0

Genotype 2

5/5 (100)

31/31 (100)

32/33 (97)

Genotype 3

74/78 (95)

52/54 (96)

44/52 (85)

Genotype 4

20/22 (91)

19/19 (100)

0

Genotype 5

1/1 (100)

0

0

Genotype 6

6/6 (100)

0

0

Unknown

1/1 (100)

0

0

Virologic breakthrough during treatment

1/263 (<1)

0

1/151 (1)

Relapse after the end of treatment

6/261 (2)‡

1/182 (1)

14/150 (9)§

Loss to follow-up

1/263 (<1)

2/182 (1)

0

Withdrawal of consent

2/263 (1)

0

0

0

1/182 (1)

0

Death

*	None of the patients who received placebo in POLARIS-1 had an HCV RNA level of less than 15 IU per milliliter at any
time point.
†	This category indicates a sustained virologic response (i.e., an HCV RNA level lower than 15 IU per milliliter 12 weeks
after the end of treatment).
‡	Of the 6 patients with relapse, 1 had HCV genotype 1a infection, 4 had genotype 3a infection, and 1 had genotype 4a
infection.
§	Of the 14 patients with relapse, 5 had HCV genotype 1a infection, 1 had genotype 1b infection, and 8 had genotype 3a
infection.

tient with HCV genotype 5 infection had a sustained virologic response. Overall, the rate of
sustained virologic response was 99% (95% CI,
95 to 100) among patients who did not have cirrhosis and 93% (95% CI, 87 to 97) among those
who had cirrhosis. Of the 56 patients with geno-
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type 3 infection and cirrhosis, 52 had a sustained
virologic response (93%; 95% CI, 83 to 98).
Among the 263 patients who received sofosbuvir–velpatasvir–voxilaprevir, 10 did not have a
sustained virologic response. Of these 10 patients, 7 had virologic failure: 1 (<1%) had viro-
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logic breakthrough during treatment, and 6 (2%)
had virologic relapse after the end of treatment.
The patient with virologic breakthrough had low
plasma concentrations of GS-331007 (the chief
sofosbuvir metabolite), velpatasvir, and voxilaprevir at weeks 8 and 12, which was suggestive
of nonadherence. Two patients receiving sofosbuvir–velpatasvir–voxilaprevir withdrew consent,
one after completing treatment and having a
virologic response 4 weeks after the end of treatment and another after taking four doses of
study drug (as described below). One other patient was lost to follow-up after week 8 of treatment. The characteristics of the 7 patients who
had virologic failure are provided in Table S5 in
the Supplementary Appendix.
POLARIS-4

Among the patients who had previously been
treated with a regimen containing any DAA except an NS5A inhibitor, the overall rate of sustained virologic response was 98% (95% CI, 95 to
99) among those who received sofosbuvir–velpat
asvir–voxilaprevir, which was significantly superior to the prespecified performance goal of 85%
(P<0.001) (Table 2 and Fig. 1). The rate of sustained virologic response among the patients
who received sofosbuvir–velpatasvir was 90%
(95% CI, 84 to 94), which was not significantly
superior to the prespecified performance goal of
85% (P = 0.09). The HCV RNA levels and changes
from baseline at each study visit through the end
of treatment are provided in Table S4 in the
Supplementary Appendix.
Among patients without cirrhosis, the rate of
sustained virologic response was 98% among
those receiving sofosbuvir–velpatasvir–voxilaprevir and 94% among those receiving sofosbuvir–
velpatasvir, as compared with 98% and 86%,
respectively, among patients with cirrhosis. Table 2 shows rates of sustained virologic response
according to HCV genotype. Of the 177 patients
in the sofosbuvir–velpatasvir–voxilaprevir group
and the 136 patients in the sofosbuvir–velpatasvir group who had a sustained virologic response
at post-treatment week 12, a total of 173 and 133
patients, respectively, returned for the posttreatment week 24 visit, and all the patients had
a sustained virologic response at that time. One
patient in the sofosbuvir–velpatasvir–voxilaprevir group did not attend the post-treatment week
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12 visit; however, this patient returned at posttreatment week 24 and had an HCV RNA level
lower than 15 IU per milliliter. In accordance
with the prespecified analysis plan, a sustained
virologic response at post-treatment week 12
was imputed for this patient.
Among the 333 patients who were treated in
POLARIS-4, 19 did not have a sustained virologic response — 4 patients (3%) in the sofosbuvir–velpatasvir–voxilaprevir group and 15 patients
(10%) in the sofosbuvir–velpatasvir group. Of
the 4 patients in the sofosbuvir–velpatasvir–
voxilaprevir group who did not have a sustained
virologic response, 1 (1%) had a virologic relapse
by week 4 of follow-up, 1 died (see below), and
2 were lost to follow-up. Among the 15 patients
in the sofosbuvir–velpatasvir group who did not
have a sustained virologic response, 14 (9%) had
a relapse after completing treatment and 1 (1%)
had virologic breakthrough during treatment.
Eight of the 14 patients who had a relapse had
HCV genotype 3a infection, 5 had genotype 1a
infection, and 1 had genotype 1b infection (Table S6 in the Supplementary Appendix).
Viral Resistance Testing

Among the 248 patients who received sofosbuvir–
velpatasvir–voxilaprevir in POLARIS-1 and for
whom viral sequence data were available, 205
(83%) had viral substitutions associated with
resistance to NS3 inhibitors or NS5A inhibitors
at baseline that were present in at least 15% of
sequence reads. Of these patients, 97% (199 of
205) had a sustained virologic response, as compared with 98% of patients without resistanceassociated substitutions at baseline (Table S7 in
the Supplementary Appendix). Among the 6 patients who had a relapse, 1 patient with HCV
genotype 4 infection had development of the
NS5A Y93H resistance-associated substitution
(Table S5 in the Supplementary Appendix).
In POLARIS-4, 49% of enrolled patients had
baseline viral substitutions associated with resistance to NS3 inhibitors or NS5A inhibitors.
The rates of sustained virologic response among
patients for whom viral sequence data were
available and who received sofosbuvir–velpatasvir–
voxilaprevir for 12 weeks was 100% (83 of 83)
among those with baseline resistance-associated
substitutions and 99% (85 of 86) among those
without baseline resistance-associated substitu-
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tions, as compared with 90% (63 of 70) and 89%
(67 of 75), respectively, among those with and
those without resistance-associated substitutions
in the sofosbuvir–velpatasvir group (Table S8 in
the Supplementary Appendix). The single patient
in the sofosbuvir–velpatasvir–voxilaprevir group
who had a relapse did not have any resistanceassociated substitutions at either baseline or the
time of relapse. Among the 14 patients in the
sofosbuvir–velpatasvir group who had a relapse,
11 had resistance-associated substitutions, most
of which were in the NS5A gene at amino acid
position 93 (Table S6 in the Supplementary Appendix).
Safety

One patient who received sofosbuvir–velpatasvir–
voxilaprevir in POLARIS-1 discontinued treatment
prematurely because of an adverse event. This
patient, a 59-year-old woman with a history of
hypertension, started therapy with ramipril on
study day 11 and discontinued sofosbuvir–velpat
asvir–voxilaprevir treatment on day 12 because
of angioedema. Three patients who received
placebo in POLARIS-1 discontinued because of
adverse events. In POLARIS-4, 1 patient, a 63-yearold woman in the sofosbuvir–velpatasvir group,
discontinued treatment on study day 49 because
of worsening of headache. None of the patients
in POLARIS-4 who received sofosbuvir–velpatasvir–voxilaprevir discontinued treatment prematurely because of adverse events.
A total of seven serious adverse events occurred among 5 patients (2%) who received
sofosbuvir–velpatasvir–voxilaprevir in POLARIS-1
(Table 3, and Table S9 in the Supplementary Appendix). In the placebo group, 7 patients had
one serious adverse event each. In POLARIS-4,
4 patients (2%) receiving sofosbuvir–velpatasvir–
voxilaprevir and 4 patients (3%) receiving sofosbuvir–velpatasvir had one serious adverse event
each (Table S10 in the Supplementary Appendix).
Across both trials, no single serious adverse event
occurred in more than 1 patient. One patient, a
61-year-old man, died from an illicit drug overdose 2 days after completing the 12 weeks of treatment with sofosbuvir–velpatasvir–voxilaprevir.
In POLARIS-1, 78% of patients who received
sofosbuvir–velpatasvir–voxilaprevir had adverse
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events, as compared with 70% of patients who
received placebo (Table 3). The most common
events in the sofosbuvir–velpatasvir–voxilaprevir
group were headache (25% of patients), fatigue
(21%), diarrhea (18%), and nausea (14%), and the
most common events in the placebo group were
fatigue (20%), headache (17%), diarrhea (12%),
and dizziness (9%). In POLARIS-4, the incidence
of adverse events was 77% among patients who
received sofosbuvir–velpatasvir–voxilaprevir and
74% among those who received sofosbuvir–velpatasvir. The most common events among patients who received sofosbuvir–velpatasvir–voxilaprevir were headache (27%), fatigue (24%), and
diarrhea (20%), and the most common events
among those who received sofosbuvir–velpatasvir
were headache (28%), fatigue (28%), and nausea
(8%). The majority of events of diarrhea were
mild in severity; the incidence of grade 2 diarrhea was low (1 to 3%). There were no events of
grade 3 or 4 diarrhea. The grade 3 and 4 adverse
events in POLARIS-1 and POLARIS-4 are presented in Tables S11 and S12 in the Supplementary Appendix.
The incidence of grade 3 and 4 laboratory
abnormalities was 5% and 2%, respectively,
among patients receiving sofosbuvir–velpatasvir–
voxilaprevir in POLARIS-1, as compared with
12% and 2% among those receiving placebo
(Table 3, and Table S13 in the Supplementary
Appendix). In POLARIS-4, the incidence of grade
3 and 4 laboratory abnormalities was 5% and less
than 1%, respectively, among patients receiving
sofosbuvir–velpatasvir–voxilaprevir, as compared
with 6% and 1% among patients receiving sofosbuvir–velpatasvir (Table 3, and Table S14 in the
Supplementary Appendix). None of the grade 3
and 4 elevations in lipase and creatine kinase
levels were accompanied by clinical evidence of
pancreatitis or myopathy, respectively.

Discussion
In these international phase 3 trials, 12 weeks of
treatment with sofosbuvir–velpatasvir–voxilaprevir resulted in high rates of sustained virologic
response among patients with and patients without compensated cirrhosis who had HCV of any
genotype and who had not had a sustained viro-
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Table 3. Adverse Events, Discontinuations of Active Treatment or Placebo, and Hematologic Abnormalities.*
Event

POLARIS-1
Placebo
(N = 152)

POLARIS-4

Sofosbuvir–Velpatasvir– Sofosbuvir–Velpatasvir–
Voxilaprevir
Voxilaprevir
(N = 263)†
(N = 182)

Sofosbuvir–
Velpatasvir
(N = 151)

number of patients (percent)
Any adverse event

107 (70)

206 (78)

140 (77)

111 (74)

Discontinuation of treatment because of adverse event

3 (2)

1 (<1)

0

1 (1)

Serious adverse event

7 (5)

5 (2)

4 (2)

4 (3)

0

0

1 (1)

0

Headache

26 (17)

66 (25)

50 (27)

43 (28)

Fatigue

30 (20)

56 (21)

43 (24)

43 (28)

Diarrhea

19 (12)

47 (18)

36 (20)

7 (5)

Nausea

12 (8)

37 (14)

22 (12)

12 (8)

Asthenia

9 (6)

20 (8)

10 (5)

9 (6)

Insomnia

8 (5)

19 (7)

12 (7)

3 (2)

Dizziness

14 (9)

11 (4)

9 (5)

2 (1)

Back pain

8 (5)

11 (4)

12 (7)

8 (5)

Arthralgia

8 (5)

8 (3)

9 (5)

4 (3)

Abdominal pain

3 (2)

7 (3)

3 (2)

9 (6)

Irritability

4 (3)

7 (3)

4 (2)

8 (5)

1 (1)

2 (1)

2 (1)

1 (1)

0

Death
Adverse events occurring in ≥5% of patients in any
group

Laboratory abnormality
Hemoglobin level <10 g/dl
3

Lymphocyte count <500/mm

2 (1)

1 (1)

1 (1)

Neutrophil count <750/mm3

0

1 (<1)

0

2 (1)

Platelet count <50,000/mm3

0

2 (1)

3 (2)

2 (1)

INR >1.5× ULN

2 (1)

0

0‡

1 (1)‡

Alanine aminotransferase >5× ULN

3 (2)

0

1 (1)

0

Aspartate aminotransferase >5× ULN

7 (5)

2 (1)

0

0

Creatine kinase level ≥10× ULN

2 (1)

3 (1)

1 (1)

0

Glucose level >250 mg/dl

7 (5)

4 (2)

4 (2)

3 (2)

Lipase level >3× ULN

4 (3)

6 (2)

3 (2)

1 (1)

0

0

Total bilirubin level >2.5× ULN

0

1 (<1)§

*	To convert the values for glucose to mmol per liter, multiply by 0.05551. INR denotes international normalized ratio, and ULN upper limit
of the normal range.
†	Laboratory values are missing for 1 patient in POLARIS-1 who received sofosbuvir–velpatasvir–voxilaprevir and withdrew from the trial 12
days into treatment.
‡	INR values are missing for 9 patients who received sofosbuvir–velpatasvir–voxilaprevir and for 4 patients who received sofosbuvir–velpatasvir in POLARIS-4.
§	This patient, a 36-year-old white man who had a grade 2 elevation in the total bilirubin level at baseline, had a transient grade 3 elevation
during the first week of treatment. The alanine aminotransferase and aspartate aminotransferase levels for this patient were normal
throughout treatment.
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logic response after previous treatment with
regimens containing DAAs, including NS5A inhibitors. This population of patients has been
underrepresented in clinical trials and has limited retreatment options. It should be noted that
these trials involved only patients who had observed virologic failure after having completed
previous treatment; it excluded those who did
not have a sustained virologic response as a
result of nonadherence or those who had discontinued previous treatment owing to adverse
events.
Because of their potency, NS5A inhibitors have
been a common component of DAA regimens.
Substitutions in the viral genome that confer
resistance to NS5A inhibitors, unlike those that
confer resistance to NS3 protease inhibitors and
NS5B polymerase inhibitors, appear to maintain
the viability of the virus after unsuccessful treatment with an NS5A inhibitor–containing regimen and have been shown to have an effect on
the rate of sustained virologic response in previous studies of DAA regimens.19 As expected,
POLARIS-1 and POLARIS-4 enrolled a substantial number of patients who had resistance-
associated viral substitutions at baseline, but the
presence of such substitutions had no discernible effect on the rates of sustained virologic
response with sofosbuvir–velpatasvir–voxilaprevir.
The incidence of adverse events among the
patients who received sofosbuvir–velpatasvir–voxilaprevir was generally similar to the rates among
patients who received placebo in POLARIS-1 and
sofosbuvir–velpatasvir in POLARIS-4, except that
more patients who received sofosbuvir–velpatasvir–voxilaprevir in POLARIS-1 had headache and
more patients who received sofosbuvir–velpatasvir–voxilaprevir in both trials had mild-to-moderate nausea and diarrhea, which are known
effects of some NS3–NS4A protease inhibitors.20
No patient interrupted treatment or discontinued treatment prematurely as a result of these
events.
The generalizability of these results may be
limited by the small numbers of patients in some
subpopulations, including those with genotype 3
infection and cirrhosis and those infected with
rarer genotypes, as well as by the fact that some
patients did not receive previous treatment with
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commercially available regimens. Another limitation that affects the generalizability of these
trials is the small number of retreated patients
who had treatment failure with the more recently
approved HCV regimens that include velpatasvir
or elbasvir. The results also cannot be generalized to patients who were excluded from the
trials, such as those coinfected with hepatitis B
virus or human immunodeficiency virus and
those with decompensated cirrhosis.
In conclusion, these results show that daily
treatment with the single-tablet regimen of
sofosbuvir–velpatasvir–voxilaprevir for 12 weeks
is highly effective for patients infected with HCV
of any genotype, with or without compensated
cirrhosis, who did not have a sustained virologic
response after treatment with DAA-based regimens, including NS5A inhibitors.
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